help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kaltsas, G. A.
Right arrow Articles by Grossman, A. B.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Kaltsas, G. A.
Right arrow Articles by Grossman, A. B.
The Journal of Clinical Endocrinology & Metabolism Vol. 88, No. 12 6115-6116
Copyright © 2003 by The Endocrine Society


Letter to the Editor

Authors’ Response: The Value of the Low-Dose Dexamethasone Suppression Test in the Differential Diagnosis of Hyperandrogenism in Women

G. A. Kaltsas, A. M. Isidori, J. P. Monson, G. M. Besser and A. B. Grossman

Department of Endocrinology, St. Bartholomew’s Hospital London EC1A 7BE, United Kingdom

Address correspondence to: Ashley B. Grossman, M.D., St. Bartholomew’s Hospital, Department of Endocrinology, West Smithfield, London, ECIA 7BE, United Kingdom. E-mail: A.B.Grossman{at}qmul.ac.uk.

To the editor:

The comments of Dr. Rosenfield and colleagues are useful in the discussion of the establishment of the optimal tests to distinguish between the different causes of hyperandrogenism in women (1, 2). According to their experience, measurement of free testosterone (fT) levels after 4-d dexamethasone administration presents the most sensitive method to diagnose an ACTH-dependent source of androgen excess (1). However, we would emphasize that our study was designed to identify those patients with virilizing tumors rather than congenital adrenal hyperplasia, which was an uncommon diagnosis in our cohort. In addition, although the duration of dexamethasone administration in our study is shorter than their 4 d of dexamethasone, in our experience a significant proportion of patients with nontumorous hyperandrogenism, principally due to polycystic ovarian syndrome, achieved adequate androgen suppression (as defined by either normalization of the elevated basal level or at least a 40% reduction) (3). The most prominent reduction in particular was obtained in DHEAS levels (3). Unfortunately, we do not have data on 17{alpha}-hydroxyprogesterone levels (17PROG) in this cohort who underwent dexamethasone testing, and we are therefore unable to comment regarding the utility of these data in diagnosing congenital adrenal hyperplasia.

Finally, there is a minor misunderstanding in that they note that our last dose of dexamethasone is given "2 h before blood sampling." This is incorrect; the doses are given strictly 6-hourly, such that the last dose is given 6 h before sampling. We are sorry if this was not clear; further details, as well as data on the sensitivity of this test in diagnosing Cushing’s syndrome, are given in a recent publication from our group (4).

Received September 11, 2003.

References

  1. Ehrmann DA, Rosenfield RL 1990 An endocrinologic approach to the patient with hirsutism. J Clin Endocrinol Metab 71:1–4[Medline]
  2. Ehrmann DA, Rosenfield RL, Barnes RB, Brigell DF, Sheikh Z 1992 Detection of functional ovarian hyperandrogenism in women with androgen excess. N Engl J Med 327:157–162[Abstract]
  3. Kaltsas GA, Isidori AM, Kola BP, Skelly RH, Chew SL, Jenkins PJ, Monson JP, Grossman A, Besser GM 2003 The value of the low-dose dexamethasone suppression test in the differential diagnosis of hyperandrogenism in women. J Clin Endocrinol Metab 88:2634–2643[Abstract/Free Full Text]
  4. Isidori AM, Kaltsas GA, Mohamed S, Morris DG, Jenkins P, Chew SL, Monson JP, Besser GM, Grossman AB 2003 Discriminatory value of the low-dose dexamethasone suppression test in establishing the diagnosis and differential diagnosis of Cushing’s syndrome. J Clin Endocrinol Metab 88:5299–5306[Abstract/Free Full Text]




This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kaltsas, G. A.
Right arrow Articles by Grossman, A. B.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Kaltsas, G. A.
Right arrow Articles by Grossman, A. B.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals